BIOG Biotech Growth Trust (the) Plc

 
TIDMBIOG 
 
18 January 2021 
 
THE BIOTECH GROWTH TRUST PLC 
 
(the "Company") 
 
                          Appointment of New Director 
 
The Board of The Biotech Growth Trust PLC is pleased to announce the 
appointment of Dr Nicola Shepherd as an independent non-executive Director of 
the Company, with effect from 18 January 2021. 
 
Dr Shepherd is the founder and a Director of Bellows Consulting Limited which 
operates in the biomedical translational sector, providing strategic advice and 
assisting clients in moving their projects closer to the market. 
 
Previously Dr Shepherd was a senior member of the Innovations Division at the 
Wellcome Trust where she was responsible for the establishment, management and 
oversight of the Translation Fund, a £30M a year investment into new product 
development covering therapeutics, vaccines, diagnostics, medical devices and 
regenerative medicine over a range of clinical indications. Working closely 
with project teams, from academic, not-for-profit and commercial organisations, 
she provided critical guidance and oversight in steering over 50 funded 
programmes from basic research towards or into the clinic. 
 
Dr Shepherd has also held positions at AstraZeneca in Late-Stage Development 
and Manufacturing; at Global Prior Art (a patent specialist in intellectual 
property) based in Boston (US) carrying out competitor analysis, due diligence 
and prior art searching; and Brown University carrying out post-doctoral 
research into complex formulations. 
 
Dr Shepherd is a Member of the CARB-X Advisory Board (www.carb-x.org), and a 
reviewer for Innovate UK. 
 
The Chairman of The Biotech Growth Trust PLC, Andrew Joy, commented: 
 
"My fellow Directors and I are delighted to welcome Dr Shepherd to the Board. 
We are very pleased to have appointed a Director with extensive and relevant 
expertise both in the UK and internationally." 
 
Dr Shepherd's appointment will be proposed to shareholders for election at the 
Annual General Meeting of the Company to be held in July 2021. 
 
There is no further information to be disclosed under Listing Rule 9.6.13R(2) 
to (6). 
 
                                    - ENDS- 
 
For further information please contact: 
 
Mark Pope 
 
Frostrow Capital LLP 
 
Company Secretary 
 
020 3 008 4913 
 
 
 
END 
 
 

(END) Dow Jones Newswires

January 18, 2021 02:01 ET (07:01 GMT)

Biotech Growth (LSE:BIOG)
Historical Stock Chart
From Apr 2024 to May 2024

Biotech Growth (LSE:BIOG)
Historical Stock Chart
From May 2023 to May 2024